November 9, 2021 -- Jasper Therapeutics and Avrobio have entered a nonexclusive research collaboration to evaluate Jasper's anti-CD117 monoclonal antibody (mAb) in clinical trials.
The mAb, JSP191, will be tested as a targeted conditioning agent option for patients with Fabry disease and/or Gaucher disease type 1 who are being treated with one of Avrobio's investigational ex vivo lentiviral gene therapies.
JSP191 is a conditioning agent that blocks stem cell factor receptor signaling, which clears hematopoietic stem cells from bone marrow and leaves an empty space for donor or genetically modified transplanted stem cells to engraft. To date, JSP191 has been evaluated in more than 90 healthy volunteers and patients.
In addition, Jasper is launching two clinical trials to test JSP191 in patients with myelodysplastic syndromes/acute myeloid leukemia and severe combined immunodeficiency.